Utama › Limfoma Bukan Hodgkin › Massachusetts › Boston
Kajian klinikal Limfoma Bukan Hodgkin di Boston, MA
26 kajian untuk Limfoma Bukan Hodgkin sedang mencari peserta di lokasi dalam dan sekitar Boston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Mengambil pesertaFasa 1/2
- Dana Farber Cancer Institute, Boston
Epco, Zanu, Ritux for R/R FL or MZL
Mengambil pesertaFasa 2
- Dana-Farber Cancer Institute, Boston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Mengambil pesertaFasa 1/2
- Research Site, Boston
- Research Site, Boston
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Mengambil pesertaFasa 1/2
- Dana-Farber Cancer Institute, Boston
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Mengambil pesertaFasa 2
- Boston Medical Center, Boston
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Mengambil pesertaFasa 2
- Dana-Farber Cancer Institute, Boston
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Mengambil pesertaFasa 1
- Tufts Medical Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Mengambil pesertaFasa 1/2
- Dana-Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Mengambil pesertaFasa 1/2
- Massachusetts General Hospital, Boston
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Mengambil pesertaKajian pemerhatian
- Dana Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Mengambil pesertaFasa 1Sukarelawan sihat dialu-alukan
- Brigham and Women's Hospital, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
Mengambil pesertaFasa 2
- Dana Farber Cancer Institute, Boston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Mengambil pesertaKajian pemerhatian
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Mengambil pesertaFasa 1
- Dana Farber Cancer Institute, Boston
Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies
Mengambil pesertaKajian pemerhatian
- Dana-Farber Cancer Institute, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Mengambil pesertaFasa 1/2
- Dana Farber Cancer Institute, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
Mengambil peserta
- Dana Farber Cancer Institute, Boston
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Mengambil pesertaFasa 1
- Massachusetts General Hospital, Boston
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Mengambil pesertaFasa 2
- Beth Israel Deaconess Medical Center, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Mengambil pesertaFasa 2Sukarelawan sihat dialu-alukan
- DFCI/BWH Brigham and Women's Hospital, Boston
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Mengambil pesertaFasa 4
- Dana-Farber Cancer Institute, Boston
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Mengambil pesertaFasa 4
- Dana-Farber Cancer Institute, Boston
Study of SGR-1505 in Mature B-Cell Neoplasms
Mengambil pesertaFasa 1
- Beth Israel Deaconess Medical Center, Boston
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Mengambil pesertaFasa 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Kajian Limfoma Bukan Hodgkin di bandar lain
- New York City, NY31 kajian
- Houston, TX31 kajian
- Nashville, TN21 kajian
- Philadelphia, PA20 kajian
- Baldwin Park, CA19 kajian
- Washington, DC18 kajian
- Chicago, IL18 kajian
- Atlanta, GA18 kajian
- Milwaukee, WI18 kajian
- Columbus, OH18 kajian
- Dallas, TX17 kajian
- Seattle, WA16 kajian
Kajian lain di Boston
- Kanser Payudara112 kajian
- Kanser Paru-paru Bukan Sel Kecil90 kajian
- Kanser (semua jenis)85 kajian
- Kanser Metastatik63 kajian
- Kanser Kolorektal63 kajian
- Kanser Paru-paru62 kajian
- Kanser Ovari61 kajian
- Kanser Prostat59 kajian
- Depresi52 kajian
- Kanser Endometrium50 kajian
- Kegagalan Jantung44 kajian
- Leukemia Mieloid Akut44 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.